National Institutes of Health

GreenMark Biomedical Inc. is a minimally invasive healthcare company focused on developing innovative technologies utilizing biopolymer nanoparticles derived from natural starch. Founded in 2016 and based in East Lansing, Michigan, with a laboratory in Ann Arbor, the company specializes in dental and medical applications. Its dental technologies include a mouth rinse product that illuminates cavities and early-stage lesions, allowing dentists to accurately diagnose and treat tooth decay. Additionally, GreenMark's medical technologies are designed for targeted delivery of anti-cancer drugs, enhancing treatment precision. The company aims to provide health benefits through its advanced nanoparticle-based solutions, promoting less invasive and more effective healthcare practices.

Myosin Therapeutics is a biopharmaceutical company focused on developing novel medications that target cellular motor proteins. It leverages molecular machines that convert energy into mechanical work inside cells to create therapies aimed at treating central nervous system disorders and other diseases, including cancer. The company concentrates on advancing pharmacotherapies that modulate motor protein activity to impact disease pathways and address significant unmet medical needs.

Vast Therapeutics, Inc. is a preclinical-stage pharmaceutical company based in Durham, North Carolina, focused on developing inhalable treatments for antibiotic-resistant pathogens affecting patients with cystic fibrosis and other respiratory diseases. Established in 2017 and previously known as Novoclem Therapeutics, the company aims to address chronic infections that are prevalent in the cystic fibrosis population. Vast Therapeutics operates as a subsidiary of KNOW Bio, LLC, and is dedicated to advancing its innovative therapeutic solutions to improve health outcomes for patients facing these challenging conditions.

Sparian Biosciences is an early-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the central nervous system (CNS). The firm specializes in creating unique and transformative medicines that specifically target brain-related conditions. Sparian is committed to advancing therapeutic solutions that address both acute and chronic pain through cutting-edge science and novel drug discovery methods.

Brixton Biosciences is a clinical-stage life sciences company developing therapies for pain management. The company focuses on non-addictive, locally targeted treatments delivered via a drug-free injectable that produces reversible nerve inhibition, aiming to provide long-lasting relief. Its lead approach seeks to extend pain relief from a single injection to thirty to sixty days, reducing reliance on systemic medications and addressing unmet needs in both chronic and acute pain.

Allyx Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2018 and based in Durham, Connecticut. The company specializes in developing disease-modifying treatments for Alzheimer's Disease, with a focus on reversing neurodegeneration. Its lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative approach aims to provide clinicians with a therapeutic option capable of preserving cognition in patients while addressing the underlying disease mechanisms.

CytoAgents is a clinical-stage biotechnology company focused on developing innovative pharmaceutical products for treating life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation.

The Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute dedicated to understanding and treating various devastating illnesses, including Alzheimer's, heart disease, lupus, multiple sclerosis, and cancer. It operates a research facility, providing services and access to resources that facilitate drug discoveries and improve patient care.

Resvita Bio develops and manufactures engineered probiotics for treating skin-related diseases, including cancer. Leveraging a synthetic biology platform, the company uses genetically engineered bacteria to produce and deliver therapeutic proteins directly to affected skin areas, providing continuous treatment and addressing limitations of traditional therapies. It targets conditions such as Netherton Syndrome and Severe Atopic Dermatitis, pursuing novel methods to manage skin disorders through localized, sustained protein delivery.

Cenna Biosciences is a biosciences company focused on the discovery and development of innovative drugs aimed at preventing and treating Alzheimer's disease. The company employs a proprietary mechanism to address the underlying cause of the disease, specifically targeting the inappropriate deposition of toxic ß-amyloid species in the brains of affected patients. Cenna Biosciences has identified a novel target and is actively developing several lead peptide compounds as disease-modifying candidates for Alzheimer's treatment.

Tiziana Life Sciences is a UK-based clinical-stage biotechnology company focused on discovering and developing novel molecules to treat diseases in oncology and immunology. Its pipeline includes Foralumab for autoimmune and inflammatory diseases, Milciclib for hepatocellular carcinoma, Anti IL-6r for severe COVID-19 symptoms, and StemPrintER for breast cancer diagnosis.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative RNA therapeutics for treating metastatic cancer. Its lead therapeutic candidate targets an RNA molecule that drives metastatic disease across multiple tumor types.

Evoq Therapeutics is a biotechnology company that develops immunotherapies intended to restore immune tolerance in autoimmune diseases. Its proprietary nanodisc platform delivers disease-specific antigens to modulate immune responses, with NanoDisc constructs designed to train the immune system to tolerate targeted proteins while preserving overall immunity. The approach has shown activity in preclinical models of autoimmune conditions including celiac disease, type 1 diabetes, lupus, pemphigus, Graves’ disease, and rheumatoid arthritis, among others. Through these nanodisc-based therapies, Evoq Therapeutics aims to provide treatment options that reduce pathological immune activity and improve patient outcomes without broad immunosuppression.

Precision Epigenomics, established in 2020 and based in Tucson, Arizona, specializes in molecular diagnostics for cancer. The company focuses on developing innovative molecular diagnostic assays, leveraging DNA methylation analysis, an epigenetic modification, to enhance cancer diagnosis and treatment. Their offerings aim to address unmet clinical needs, aiding clinicians in improved patient management.

Unlocked Labs develops targeted probiotics designed to manage specific health conditions. Their first product focuses on reducing kidney stone risk by digesting a stone-forming compound found in healthy foods like leafy vegetables.

Marker Therapeutics is a clinical-stage immuno-oncology company developing adoptive non-gene modified T cell therapies for treating hematologic malignancies. Its MultiTAA technology selectively expands non-engineered T cells to target and kill tumor cells expressing multiple tumor-associated antigens, preventing immune escape.

Immunovia is a diagnostics company focused on the early detection of pancreatic cancer and other complex diseases. It develops and commercializes innovative diagnostic tools using its proprietary technology platform, IMMray, which is based on antibody microarray analysis. The company conducts clinical trials and validation studies to ensure the accuracy and reliability of its tests. By collaborating with medical institutions and research centers worldwide, Immunovia aims to bring its diagnostic solutions to market, significantly impacting the treatment and management of pancreatic cancer and potentially improving survival rates. Its approach to utilizing blood-based biomarkers may also enable early detection strategies for other cancers and autoimmune diseases.

Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapies for cannabinoid overdose and substance addiction. Its lead candidate, ANEB-001, is designed to reverse the effects of cannabinoid overdose within about one hour of administration. Early clinical data indicate rapid absorption and tolerability, with weight loss observed potentially linked to central cannabinoid receptor type 1 antagonism. The company aims to address acute overdose symptoms such as sedation, anxiety, panic, and psychosis by restoring balance to the endocannabinoid system.

Matter Bio is a biotechnology company dedicated to preserving genomic integrity. It offers research services aimed at enhancing longevity by safeguarding and utilising DNA information. The company's primary focus is assembling an elite team of scientists and executives to combat genetic mutations and extend patient lifespan through innovative approaches to reverse such mutations.

Selsym Biotech is a biotechnology company developing platelet-mimetic therapies and hemostatic technologies to control bleeding in trauma, surgery, and wound care. The company’s approach combines biomimetic platelet-inspired mechanisms with innovative materials such as Hemostatic Healing Hydrogels (H3) to promote rapid hemostasis and tissue repair. By addressing ongoing platelet supply shortages and shelf life challenges, Selsym Biotech aims to provide readily available, effective bleeding management solutions for emergency and surgical settings. The firm focuses on enabling healthcare providers to manage hemorrhage more effectively, reduce transfusion needs, and improve patient outcomes through therapies that mimic native platelet function and enhance wound healing.

Lamassu Pharma is a biotech startup developing small-molecule therapies for severe acute pancreatitis, with a lead candidate developed at Mayo Clinic that has shown strong preclinical results in reducing mortality and morbidity. The company is advancing this compound through safety testing in preparation for definitive clinical trials, aiming to deliver life-saving treatments to patients. In addition, Lamassu develops other small-molecule therapeutics targeting urgent medical needs, including potential cancer treatments, pursuing multiple candidates through clinical development. The organization emphasizes a patient-centric, evidence-based research approach to accelerate translation of science into therapies for unmet medical needs.

Perspective Therapeutics specializes in developing radiopharmaceuticals for targeted cancer treatment. Utilizing its proprietary technology centered around the alpha-emitting isotope Lead-212, the company aims to deliver precise radiation therapy directly to cancer cells.

AcuraStem is a biotechnology company based in Monrovia, California, founded in 2016. The company specializes in developing a precision medicine platform that utilizes complex cellular models derived from Amyotrophic Lateral Sclerosis (ALS) patients' cells. AcuraStem employs advanced cellular reprogramming and artificial intelligence technologies to create patient-specific treatments for neurodegenerative diseases. Their platform is designed to evaluate disease progression and test existing therapeutics, as well as combinations of therapeutic approaches, to identify effective treatments that could slow disease progression. The company's team includes PhDs, professors, tech entrepreneurs, and veterans from the drug industry, all working towards addressing the challenges posed by ALS.

Orlance provides more effective therapeutic and preventive vaccines for a wide spectrum of viral targets.

Endomimetics develops bio-nanometric coating technology for stents, aiming to enhance care for patients with kidney disease. Its innovative coating mimics human tissue, reducing complications and surgeries associated with implanted devices.

Hillhurst Biopharmaceuticals specializes in developing innovative, liquid therapeutic gases for treating sickle cell disease. Their core technology enables the oral delivery of low-dose carbon monoxide, targeting the protective heme oxygenase system to reduce inflammation, prevent cell death, and halt hemoglobin polymerization. This approach addresses challenges associated with traditional inhaled gas therapies, such as caregiver exposure and imprecise dosing, ensuring accurate and safe administration.

Rational Vaccines is a biotechnology company focused on developing vaccines for herpes simplex virus (HSV) and related diseases. It aims to revolutionize treatment, prevention, and diagnosis by creating rationally engineered, live-attenuated viral vaccines.

Founded in Finland in 2003, Magnasense specializes in developing and manufacturing lateral flow tests for various applications. These include human health, environmental analysis, and veterinary testing. The company's innovative magnetic labeling technique enables quantitative measurements, enhancing reliability and sensitivity. Magnasense offers a Pilot Feasibility test service and operates as a subsidiary of LifeAssays AB.

Clene Nanomedicine, established in 2012 and headquartered in Salt Lake City, Utah, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. The company has pioneered a unique nanotechnology drug platform that enables the creation of orally-administered neurotherapeutic drugs. This technology, known as Clean-Surface Nanosuspension, produces clean-surface nanocrystal medicines and serves as a foundation for a pipeline of new drug candidates aimed at addressing various diseases with significant unmet medical needs. Clene Nanomedicine's primary focus areas include demyelinating disorders and oncology.

Integral Molecular, Inc. is a biotechnology company headquartered in Philadelphia, Pennsylvania, specializing in the development of innovative technologies for drug discovery targeting challenging diseases such as cancer, HIV, and arthritis. The company is particularly known for its Lipoparticle technology, which enhances the identification and optimization of drugs aimed at integral membrane proteins. With over 20 years of expertise in membrane proteins and antibodies, Integral Molecular has supported more than 400 pharmaceutical and biotechnology companies in their research, medication discovery, and vaccine development efforts. The company's solutions are integral to various stages of the drug discovery process, focusing on the development of chemical compounds and antibodies.

Actinium Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for life-threatening diseases using its alpha particle immunotherapy platform. Its lead product candidates include Iomab-B, in Phase III trials as an induction agent for elderly AML patients prior to bone marrow transplant, and Actimab-A, in Phase II trials for newly diagnosed AML patients aged 60 and over.

Neurodon Corporation is a biopharmaceutical company focused on discovering and developing disease-modifying therapeutic candidates for intractable diseases. Established in 2019 and headquartered in Crown Point, Indiana, Neurodon specializes in molecular therapies that address endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach aims to restore calcium homeostasis through first-in-class modulators, addressing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, and other rare diseases. Neurodon has made significant progress, with two candidates currently in IND-enabling studies and plans to enter clinical trials in 2025. The company has raised over $11 million through various funding sources, including state and federal grants, partnerships, and angel investments, and is actively seeking additional funding to support its first human studies for diabetes and rare disease programs.

Omniose is a biotechnology company developing next-generation conjugate vaccines using its proprietary in vivo conjugating technology. The company focuses on creating vaccines against infectious diseases, with a current emphasis on pneumococcal conjugate vaccines for broader protection against bacterial strains.

Base Pair Biotechnologies, Inc. is a biotechnology company based in Pearland, Texas, specializing in the research, development, and discovery of aptamer affinity ligands. Established in 2012, the company offers custom aptamer development services and a catalog of ready-made aptamers. Its innovative platform incorporates novel libraries and proprietary methods for multiplexing the aptamer discovery process, allowing for efficient screening and validation. Base Pair Biotechnologies collaborates with academic, commercial, and government institutions to create advanced tools and technologies across various sectors, including diagnostics, therapeutics, animal testing, agriculture, and environmental testing. The company's expertise in aptamer research, which began in 2004, has positioned it as a leader in the field, enabling clients to obtain high-quality aptamers with reduced time and cost.

South Rampart Pharma is a clinical-stage biotechnology company focused on safer pain therapies. It develops synthesized, non-opioid and non-liver-toxic molecules that modulate pain signaling in the brain's periaqueductal gray (PAG) region, aiming to provide effective analgesia with reduced abuse potential and liver toxicity compared with traditional opioids. The company’s approach seeks to address key safety and tolerability challenges in current pain medicines while delivering meaningful relief for patients.

Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.

Spinogenix is a biopharmaceutical company focused on neurorestorative therapeutics that aim to restore brain connections and functions lost after brain injury and in neurodegenerative or psychiatric diseases. Founded in 2016 and based in San Diego, California, Spinogenix develops a new class of therapies designed to regenerate synapses and reverse declines in cognitive and motor function. The company targets direct modulation of synaptic proteins to rebuild neural connectivity, with the goal of reversing synapse loss and improving neurological outcomes. Therapies may be used as monotherapy or in combination with other treatments to address disease-specific degenerative processes, aiming to restore neural networks disrupted by CNS injury and degeneration.

Greenstone Biosciences is a drug discovery platform focused on accelerating the development of effective therapies for patients. By leveraging advanced technologies, including artificial intelligence and human-induced pluripotent stem cells, the company aims to transform the traditional drug discovery process, which is often slow and prone to high failure rates. Greenstone Biosciences seeks to create a rapid and integrated computational platform that can efficiently deliver safe and effective therapeutics, addressing diseases with significant unmet medical needs. Through its innovative approach, the company is dedicated to improving patient outcomes and advancing therapeutic options.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company focused on developing immune-based therapies for cancer and infectious diseases. Incorporated in 2011 and located in Winchester, Massachusetts, the company has created a platform that targets the tumor necrosis factor receptor 2 (TNFR2) oncogene and the specific population of TNFR2 regulatory T cells within the tumor microenvironment. This innovative approach aims to enhance immunotherapy strategies, particularly for chronic infectious diseases, by leveraging the body's immune system to combat various health challenges.

Talus Bio is a biotechnology company specializing in drug discovery. It focuses on developing therapies targeting challenging cancer transcription factors using its proprietary MARMOT platform, which integrates functional proteomics, automated biology, machine learning, AI, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics.

Inherent Biosciences is a molecular diagnostics company focused on transforming the traditional trial and error approach in medicine. The company leverages its innovative epigenetic medicine platform to address various health challenges by identifying gene dysregulation and its associated pathways. By translating biological insights into actionable information, Inherent Biosciences aims to enhance treatment strategies for conditions such as pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. This approach not only guides healthcare professionals in managing complex diseases but also seeks to provide personalized insights that empower patients in their health journeys.

Applied BioMath, LLC, established in 2013 and headquartered in Concord, Massachusetts, specializes in systems biology and pharmacology services aimed at accelerating drug research and development for biotechnology and pharmaceutical companies. The company employs advanced mathematical modeling and simulation techniques to provide predictive guidance and insights throughout the drug discovery process. Its offerings include pathway model development, target and biomarker discovery, and feasibility assessments for various drug targets. Additionally, Applied BioMath conducts analyses of competitor compounds and projects drug properties and dosing for clinical phases. The firm utilizes proprietary algorithms and high-performance computational biology to optimize decision-making and mitigate risks associated with late-stage attrition in drug development. With additional offices in Cambridge and Oakland, Applied BioMath collaborates strategically with industry leaders such as Sanofi and Xilio Therapeutics to enhance its service offerings.

Fesarius Therapeutics is a biotechnology company developing engineered tissue products for wound care, reconstructive surgery, and regenerative medicine. Its patented differential density hydrogel dermal matrices, such as DermiSphere, enhance healing from trauma, burns, or infection.

Access to Advanced Health Institute is a nonprofit biotech research institute that brings together specialists, technologies, and platforms to offer accessible goods and solutions for leveraging the immune system to alleviate disease.

iMetabolic Biopharma is an early-stage precision medicine drug development company focused on obesity-related diseases. It develops therapeutics using its iPlatform technology, a platform designed to accelerate drug discovery and reduce development costs, enabling potential life-saving solutions to reach the clinic faster and more affordably.

AAVogen is a biotechnology company focused on developing gene therapies for muscle-wasting diseases. The company develops muscle-specific viral capsids and therapeutics intended to strengthen muscles and improve function in conditions such as inclusion body myositis, muscular dystrophies, myopathies, and peripheral neuropathies, with potential applications for heart failure and obesity with type 2 diabetes.

Opsin Biotherapeutics specializes in the development of gene therapies based on opsins, a class of light-sensitive proteins. The company's primary focus is to create a pipeline of treatments for pain management, aiming to provide effective alternatives to opioids.

Caeregen Therapeutics focuses on discovering and developing innovative pharmacological therapies aimed at restoring damaged tissues and protecting them by reactivating signaling pathways involved in healthy cellular development.

Kintara Therapeutics is a clinical-stage cancer drug development company focused on creating and advancing therapies for difficult-to-treat cancers. Its late-stage product candidates include VAL-083, a DNA-targeting chemotherapeutic agent in Phase III-ready development for drug-resistant solid tumors such as glioblastoma multiforme, and REM-001, a photodynamic therapy for cutaneous metastatic breast cancer. The company pursues strategic collaborations to expand access, including a partnership with Guangxi Wuzhou Pharmaceutical to manufacture and sell VAL-083 in China. By focusing on streamlined, high-need cancer indications, Kintara aims to bring novel treatments to patients with limited options.

Marker Therapeutics is a clinical-stage immuno-oncology company developing adoptive non-gene modified T cell therapies for treating hematologic malignancies. Its MultiTAA technology selectively expands non-engineered T cells to target and kill tumor cells expressing multiple tumor-associated antigens, preventing immune escape.

Shirley Ryan AbilityLab is a translational research hospital. Their services include spinal cord injury recovery, brain injury recovery, COVID recovery, pediatric and adolescent rehabilitation, nursing, cancer rehabilitation, limb loss and impairment, and pain management.

Founded in 2021, Domus Diagnostics specializes in respiratory disease home testing services via its care diagnostics platform. The company offers affordable, user-friendly, and accurate testing kits designed to address infectious disease outbreaks promptly.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery platforms and the development of quality-of-life medicines. The company focuses on enhancing drug discovery and manufacturing through its innovative biotechnology and nanotechnology solutions. Aphios offers a range of therapeutic products aimed at health maintenance, disease prevention, and the treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-based product, and various formulations of Taxotere for cancer treatment, which aim to improve oral bioavailability and target specific cancer cells. In addition to its therapeutic offerings, Aphios develops advanced technologies such as SuperFluids for pharmaceutical manufacturing and virology testing services, contributing to the safety and efficacy of drug therapies. Founded in 1993, Aphios continues to push the boundaries of medical science with its focus on innovative solutions for complex health challenges.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative RNA therapeutics for treating metastatic cancer. Its lead therapeutic candidate targets an RNA molecule that drives metastatic disease across multiple tumor types.

Founded in 1998, Second Sight is a medical device company dedicated to developing implantable visual prosthetics. Their primary product, the Argus II Retinal Prosthesis System, is designed to provide artificial vision to individuals blinded by outer retinal degenerations such as Retinitis Pigmentosa.

AivoCode Inc., established as a biotechnology company, specializes in innovative solutions for critical neurological disorders like traumatic brain injury and neurodegenerative diseases such as Alzheimer's. The company's proprietary technology revolves around unique peptides that selectively target molecular changes in affected brain regions, facilitating the delivery of various therapeutics and diagnostics. These peptides also exhibit intrinsic therapeutic properties. Notably, AivoCode's development has been solely funded through non-dilutive federal grants.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Dignify Therapeutics is a drug development company based in Raleigh, North Carolina. Founded in 2013, it focuses on restoring voluntary control of bladder and bowel functions for patients with spinal cord injury, spina bifida, multiple sclerosis, and other neurological conditions through novel pharmaceutical agents.

The Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute dedicated to understanding and treating various devastating illnesses, including Alzheimer's, heart disease, lupus, multiple sclerosis, and cancer. It operates a research facility, providing services and access to resources that facilitate drug discoveries and improve patient care.

Is my medication working? Levl helps you reveal the answer. Levl measures the effectiveness of medications and offers insights to get the most out of mental health treatments. Levl helps people stick to their treatment while supporting clinicians in optimizing the medication.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

PharmaJet develops and markets needle-free jet injectors for vaccine delivery, enabling administration without a needle and reducing sharps injuries, needle reuse, cross-contamination, and medical waste. Its Stratis and Tropis platforms are designed to deliver vaccines intramuscular, subcutaneous, or intradermal across various volumes, offering a potential return on investment by lowering risk and waste. Founded in 2005 and based in Golden, Colorado, PharmaJet focuses on delivering safe, user-friendly devices that support immunization programs and aim to simplify injections while expanding access to vaccination.

BIOS Health is a pioneering company focused on developing neural digital therapies by harnessing data-driven insights from the human nervous system. Co-founded by researchers from Cambridge University, the firm aims to revolutionize precision medicine through the identification of neural biomarkers that link nerve activity to various medical conditions. BIOS's innovative approach holds promise for treating chronic diseases such as hypertension, diabetes, rheumatoid arthritis, and neurodegenerative disorders like Parkinson's and Alzheimer's. The company's expertise encompasses a diverse range of fields, including neuroscience, machine learning, software engineering, and biotechnology, allowing it to create advanced solutions for improving the quality of life for individuals suffering from these conditions. Additionally, BIOS is engaged in developing prosthetic connectors that standardize the interface between bionic devices and the body's nervous and soft-tissue systems, enabling enhanced control and feedback for patients with prosthetics.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Aptinyx Inc. is a clinical-stage biopharmaceutical company based in Evanston, Illinois, that specializes in discovering and developing innovative therapies for disorders of the brain and nervous system. Founded in 2015, the company focuses on proprietary synthetic small molecules that modulate the NMDA receptor, enhancing nerve cell communication. Aptinyx's pipeline includes NYX-2925, which is in Phase II clinical development for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, NYX-458, another NMDA receptor modulator, is undergoing Phase I studies aimed at treating cognitive impairment associated with Parkinson's disease. The company also collaborates with Allergan plc to develop a compound for major depressive disorder, highlighting its commitment to addressing significant unmet medical needs in the central nervous system arena.

Cellular Logistics, Inc. is a biotechnology company founded in 2016 and headquartered in Sun Prairie, Wisconsin. The company specializes in the development of an acellular biomaterial aimed at enhancing cell survival rates and retention in regenerative medicine therapies. This innovative biomaterial serves as a stand-alone therapeutic for applications related to cardiac and tissue vascularization and offers an effective cell delivery mechanism for regenerative treatments. By improving post-injection cell retention, Cellular Logistics aims to enhance patient outcomes in regenerative medicine.

Neurovations, a patient care and innovation company, was founded in 1992 by CEO Dr. Eric Grigsby. Today, Neurovations is a national leader in medical device and pharmaceutical innovation, clinical research, and a world-class education program focusing in pain and neuroscience. Dr. Grigsby is deeply connected to the healthcare community through our non-profit HealthRoots Foundation. Our unwavering mission is to inspire hope and to contribute to the health and well-being of our patients and communities through integrated clinical practice, research, and education.

Whitman-Walker Health provides health and wellness services. They provide HIV, prep, pep, medical and community care, insurance navigation services, gender affirming care and services, youth and family support, legal services, dental health, and behavorial health services.

Efemoral Medical is a medical technology company focused on durable, minimally invasive therapies for peripheral vascular disease. The company is developing a bioresorbable intravascular stent designed to maintain or restore patency in peripheral vessels, supporting effective treatment and improved quality of life for patients with PAD. Its initial offering, the Efemoral Vascular Scaffold System with FlexStep Technology, embodies a multi-element approach to endovascular intervention for peripheral arteries.

We are a women's owned startup focusing on new therapeutic approaches to gynecological conditions. Our primary focus is endometriosis. We approach endometriosis with a holistic view and our therapies focus on the stress system rather that on the reproductive system.

Unlocked Labs develops targeted probiotics designed to manage specific health conditions. Their first product focuses on reducing kidney stone risk by digesting a stone-forming compound found in healthy foods like leafy vegetables.

Evaxion Biotech is a clinical-stage company leveraging AI-immunology™ technology to decode the human immune system, developing novel immunotherapies for cancer and infectious diseases. Its pipeline includes three patient-specific cancer therapies in Phase I/IIa trials and vaccines targeting bacterial and viral infections.

Matregenix is a MedTech company founded in 2018 by Sherif Soliman and based in Irvine, California. The company specializes in the development and manufacturing of advanced nanofibrous materials for various medical applications. Its flagship product, MatriNova, is a barrier membrane designed specifically for periodontal surgeries, featuring customizable properties such as predictable resorption time and ease of handling. Matregenix employs electrospinning technology to create innovative membrane solutions that cater to the filtration and biomedical sectors. In addition to its product offerings, the company provides comprehensive contract development and manufacturing services, assisting manufacturers in bringing their medical products to market effectively.

AAVogen is a biotechnology company focused on developing gene therapies for muscle-wasting diseases. The company develops muscle-specific viral capsids and therapeutics intended to strengthen muscles and improve function in conditions such as inclusion body myositis, muscular dystrophies, myopathies, and peripheral neuropathies, with potential applications for heart failure and obesity with type 2 diabetes.

iQure Pharma is a global biotechnology company founded by entrepreneurs and former pharmaceutical industry managers. It specializes in the development of new therapeutics, focusing on neurodegenerative diseases with unmet medical needs.

Pantherics is a new type of therapy based on modulation of peripheral GABAA receptors.

Immuto Scientific offers biotechnology services, specializing in analytical insights for pharmaceutical companies during drug discovery. Its core technology automates complex protein analysis, expediting the determination of protein structures compared to industry standards.

Founded in 2006, Oligomerix is a biopharmaceutical company dedicated to developing therapeutics for Alzheimer's and related neurodegenerative diseases. It focuses on tau oligomer and tau protease inhibitor programs for small molecule drug discovery, and develops antibody fragments for tau oligomers as biomarkers.

Founded in 1998, Second Sight is a medical device company dedicated to developing implantable visual prosthetics. Their primary product, the Argus II Retinal Prosthesis System, is designed to provide artificial vision to individuals blinded by outer retinal degenerations such as Retinitis Pigmentosa.

The Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute dedicated to understanding and treating various devastating illnesses, including Alzheimer's, heart disease, lupus, multiple sclerosis, and cancer. It operates a research facility, providing services and access to resources that facilitate drug discoveries and improve patient care.

Eliaz Therapeutics is focused on developing innovative medical devices aimed at treating life-threatening diseases that are currently difficult to manage. The company's flagship device utilizes a patented apheresis column designed to selectively remove galectin-3 from human blood. This device targets both bound and free galectin-3, a protein linked to various serious health conditions, including diabetes, chronic kidney disease, organ fibrosis, and cancer. By efficiently eliminating galectin-3 from the bloodstream, the device offers a less invasive treatment option with fewer side effects compared to traditional therapies. Its design leverages a proprietary capturing molecule and is compatible with existing hospital systems, facilitating its adoption in clinical settings.

Reliant Glycosciences is a biotechnology company dedicated to developing diagnostic and prognostic tools specifically for patients with IgA nephropathy. The company focuses on creating assays that identify biomarkers associated with this condition, which possess diagnostic and prognostic value. By characterizing disease-specific biomarkers, Reliant Glycosciences aims to facilitate the development and testing of innovative, targeted therapies for IgA nephropathy. This approach not only supports the advancement of transformative treatments but also enhances the overall understanding of the disease, ultimately benefiting patients affected by this condition.

Founded in 2013, Immunicom specializes in developing innovative, non-pharmaceutical immunotherapy treatments for cancer, inflammatory diseases, and autoimmune disorders. The company's core product is a therapeutic device designed to filter blood and directly target various types of cancer, potentially enhancing the effects of other treatments with fewer side effects.

Talus Bio is a biotechnology company specializing in drug discovery. It focuses on developing therapies targeting challenging cancer transcription factors using its proprietary MARMOT platform, which integrates functional proteomics, automated biology, machine learning, AI, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics.

NovoMedix is a biotechnology company focused on developing novel orally available small molecules to address fibrotic disorders and certain cancer types. The company utilizes a proprietary technology platform that includes a library of small-molecule inhibitors, which have demonstrated significant efficacy in animal models for both fibrosis and cancer. Notably, some of these compounds co-target pathways that offer cardioprotective benefits and enhance the effectiveness of standard chemotherapies for triple negative breast cancer. This dual action aims to improve patient responses to treatment while significantly reducing the cardiotoxic effects commonly associated with chemotherapies, such as doxorubicin. As cardiovascular disease is a leading cause of death among breast cancer survivors, NovoMedix's approach prioritizes long-term patient health by addressing both cancer and associated heart risks. The company is working towards initiating IND enabling studies for its lead candidate, with the objective of delivering a safe and effective therapy to patients as soon as possible.

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Novoron Bioscience develops therapeutic approaches aimed at repairing damage and treating diseases of the central nervous system. The company concentrates on lipoprotein receptor biology to create CNS therapies, with preclinical programs addressing Alzheimer's disease and other tauopathies, multiple sclerosis, spinal cord injury, and related demyelinating conditions. Its platform explores both whole-receptor and micro-domain LDL receptor pathways to enable neuroprotection and recovery from CNS injury. Based in San Diego, Novoron Bioscience pursues novel biologics and agents intended to advance treatment options where current therapies are limited.

Mi-Helper develops innovative, non-drug remedies for migraine relief. Their flagship product is a semi-portable device that delivers a fine saline mist into the nostrils, providing on-demand relief from migraine-related pain and associated symptoms.

Delpor is a San Francisco-based developer of drug delivery technologies focused on creating sustained and pattern-specific release of proteins, peptides, and small molecules through small, non-mechanical subcutaneous implants. Its platforms include Prozor, a non-mechanical implantable device for delivering antipsychotics and other small molecules; NANOPOR, a membrane architecture-based implant offering prolonged release; and Delos PUMP, a self-contained implant that delivers drugs in programmed or pulse patterns, with potential for external activation to provide episodic dosing of therapies such as pain medications, antidotes, stimulants, or resuscitation agents. Founded in 2009, the company aims to improve medication adherence, safety, and efficacy by enabling convenient in-office implantation and simple administration, reducing the need for frequent injections. Delpor seeks to partner or license its technologies to advance long-acting formulations and pattern-specific dosing across therapeutic areas.

4E Therapeutics is focused on developing innovative therapies for chronic pain disorders, particularly neuropathic pain, which represents a significant unmet medical need. The company specializes in orally bioavailable MNK inhibitors that exhibit enhanced tissue specificity and pharmacokinetic profiles, demonstrating potent analgesic effects in various animal pain models. By targeting the activity of elF4E proteins, 4E Therapeutics aims to regulate pain-sensing neurons within the peripheral nervous system. In addition to neuropathic pain, the company is also engaged in discovering and developing compounds to address migraine and acute pain, positioning itself as a leader in the field of pain management.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell and gene therapies aimed at curing hematologic cancers, solid tumors, and rare genetic diseases. The company’s pipeline includes gene therapy programs for rare genetic disorders and chimeric antigen receptor (CAR) T cell therapies targeting various malignancies. Notable developments include MB-107, a potential curative gene therapy for X-linked severe combined immunodeficiency, and several CAR T therapies such as MB-102 for acute myeloid leukemia, MB-106 for B-cell lymphomas, and programs targeting glioblastoma and solid tumors like breast and pancreatic cancers. Mustang Bio has established collaborations with institutions such as Nationwide Children’s Hospital and Beth Israel Deaconess Medical Center to advance its research initiatives. Founded in 2015 and headquartered in New York, the company operates as a subsidiary of Fortress Biotech, Inc.

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.

Amplo Biotechnology is a biotechnology company developing adeno-associated viral therapies aimed at curing defects in neuromuscular junctions, with an initial focus on congenital myasthenic syndromes. Its lead program, AAV-Dok7, originated with a research team from the Institute of Medical Science at the University of Tokyo and is designed to be delivered via intravascular injection to trigger molecular events that address paralysis, breathing, and swallowing difficulties caused by neuromuscular junction defects.

Benten Technologies is a social impact company dedicated to democratizing healthcare through digital therapeutics. Its platform focuses on enhancing services for expectant mothers, supporting healthy living, providing health education, and offering screening devices, aiming to improve access to care and quality of life for diverse patient populations.

Partillion Bioscience is a life science company developing a platform for functional single-cell analysis. This platform enables rapid compartmentalization and analysis of millions of single cells to probe biological functions such as secreted proteins, facilitating the development of advanced therapies for conditions like cancer, autoimmune disorders, and infectious diseases.

Nanoscope Therapeutics Inc. is a biotechnology company based in Bedford, Texas, focused on developing innovative gene therapies aimed at restoring vision for individuals affected by retinal degenerative diseases, such as retinitis pigmentosa and dry age-related macular degeneration. Established in 2017, the company specializes in light-sensitive molecules and employs light-assisted gene delivery techniques to enable targeted treatment that re-sensitizes the retina, allowing patients to perceive low light levels. By utilizing a unique optogenetic approach, Nanoscope Therapeutics aims to deliver a solution for vision loss in patients where no effective cure currently exists, thereby advancing the potential for vision restoration in millions of affected individuals.

Vibrato Medical is focused on developing a noninvasive therapeutic ultrasound device aimed at treating Critical Limb Ischemia and Peripheral Arterial Disease. The company’s innovative approach is grounded in extensive research and recent advancements in ultrasound technology. Its device is designed to stimulate vasodilation and promote the growth of blood vessels, addressing symptoms and potentially preventing limb loss without the need for surgical intervention. This wearable technology allows patients to benefit from treatment in the comfort of their own homes, making it a convenient and accessible solution for those affected by these serious vascular conditions.

Novoron Bioscience develops therapeutic approaches aimed at repairing damage and treating diseases of the central nervous system. The company concentrates on lipoprotein receptor biology to create CNS therapies, with preclinical programs addressing Alzheimer's disease and other tauopathies, multiple sclerosis, spinal cord injury, and related demyelinating conditions. Its platform explores both whole-receptor and micro-domain LDL receptor pathways to enable neuroprotection and recovery from CNS injury. Based in San Diego, Novoron Bioscience pursues novel biologics and agents intended to advance treatment options where current therapies are limited.

Omnix Medical focuses on developing and commercializing highly effective antibiotic agents targeting resistant bacterial infections. It aims to combat the growing threat of drug-resistant bacteria, improving global public health.